rs4434553 — TFR2 TFR2 upstream variant

TFR2 rs4434553 — The Upstream TFR2 Variant That Modulates Hepcidin and Liver Iron

The TFR2 gene encodes transferrin receptor 2, a liver-expressed iron-sensing protein that plays a central role in calibrating hepcidin¹¹ hepcidin
A peptide hormone produced by the liver that acts as the master regulator of systemic iron availability — it controls how much iron the gut absorbs and how much is released from recycling macrophages. When diferric transferrin (iron-loaded transferrin in the blood) binds TFR2, it triggers a signaling cascade that increases hepcidin secretion, thereby restricting iron entry and preventing overload. rs4434553 sits approximately 2 kb upstream of the TFR2 coding sequence in a regulatory region and appears to modulate how strongly TFR2 expression responds to iron signals.

The Mechanism

As an upstream regulatory variant, rs4434553 (c.-258+123T>C in paper notation; A>G on the GRCh38 plus strand, TFR2 being minus-strand) likely influences TFR2 transcriptional activity or mRNA processing of non-coding transcripts overlapping this region. The functional consequence is inferred from the phenotypic data: carriers of the G allele (coding-strand C) show higher circulating hepcidin and lower serum ferritin²² higher circulating hepcidin and lower serum ferritin
Consistent with increased TFR2-mediated hepcidin upregulation — the G/C allele may increase TFR2 expression or shift the iron-sensing threshold compared to AA homozygotes. The A allele (coding-strand T) appears to blunt TFR2-mediated hepcidin signaling, allowing relatively greater iron accumulation under iron-replete conditions.

Because TFR2 is also expressed in the retinal pigment epithelium³³ retinal pigment epithelium
The RPE is the metabolic support layer beneath the photoreceptors; it manages the continuous renewal of the outer photoreceptor segments and is exquisitely sensitive to iron-driven oxidative damage, the same regulatory variant may influence local iron control in the eye — a separate tissue expression mechanism from its hepatic hepcidin role.

The Evidence

The clearest finding for rs4434553 comes from a Chinese Han case-control study of non-alcoholic fatty liver disease. Pan et al. 2022⁴⁴ Pan et al. 2022
Gastroenterol Rep; case-control study at two affiliated hospitals of Fujian Medical University; TFR2 promoter variants genotyped in NAFLD cases and controls; rs4434553 GA/GG genotype associated with reduced NAFLD risk vs AA (OR=0.630, 95% CI 0.504-0.788); GA/GG correlated with lower serum ferritin and higher serum hepcidin. This direction is biologically coherent: lower hepcidin in AA carriers allows more iron absorption and release from recycling macrophages, increasing hepatic iron deposition — a recognized driver of NAFLD progression through oxidative stress and mitochondrial dysfunction⁵⁵ NAFLD progression through oxidative stress and mitochondrial dysfunction
Iron catalyzes the Fenton reaction in hepatocytes, generating reactive oxygen species that promote hepatocyte injury, fibrosis, and necroinflammation.

For age-related macular degeneration, the picture is more nuanced. Wysokinski et al. 2014⁶⁶ Wysokinski et al. 2014
Dis Markers; 493 AMD cases and 171 controls; rs4434553 showed no overall AMD association but demonstrated subgroup effects — the C allele (plus-strand G) increased AMD occurrence in subjects over age 72, and the CC genotype was enriched in AMD patients with BMI below 26. These subgroup-specific signals are consistent with a modifier role: in lean, older individuals, the retinal iron regulatory environment may differ enough that TFR2 expression level becomes a relevant AMD determinant.

A pooled Parkinson's disease analysis found a haplotype containing the A allele at rs4434553 combined with the G allele at neighboring rs10247962 showed a suggestive protective association with Parkinson's disease (OR=0.87, 95% CI 0.74-1.02)⁷⁷ suggestive protective association with Parkinson's disease (OR=0.87, 95% CI 0.74-1.02)
The confidence interval crosses 1.0, making this finding non-significant at conventional thresholds — it is hypothesis-generating only. Iron dysregulation in the substantia nigra is a recognized feature of Parkinson's pathology, and TFR2 haplotype effects on brain iron regulation remain plausible but unconfirmed.

Practical Actions

For AA homozygotes — who have the least favorable iron-regulatory profile from this variant — the most actionable response is periodic monitoring of serum ferritin and iron saturation, particularly if they carry other iron-loading variants (HFE, TMPRSS6). The AMD signal specifically for the G allele in age-stratified subgroups means that GG homozygotes approaching age 70+ may benefit from proactive retinal screening. The overall evidence base remains emerging: none of these associations have been replicated in large independent cohorts or reached genome-wide significance, so this variant should be interpreted as a secondary iron-pathway signal rather than a primary disease determinant.

Interactions

rs4434553 shares the TFR2 locus with rs2075674, a synonymous coding variant that has been studied independently for AMD risk. Both variants were used together in the Wysokinski 2014 AMD study, but they appear to tag different functional effects within TFR2: rs4434553 sits upstream and likely modulates transcription, while rs2075674 is an exon 16 synonymous variant with potential splice-regulatory activity. The upstream intronic variant rs7385804 in TFR2 is the locus tag with the strongest evidence in iron-parameter GWAS. Combined carrier status across multiple TFR2 variants may capture more of the locus's functional variation than any single SNP alone. In the broader iron-sensing pathway, HFE C282Y (rs1800562) and TMPRSS6 Ala736Val (rs855791) are the highest-impact iron-loading variants; their effects compound with TFR2 regulatory variation through parallel but distinct inputs on hepcidin production.